Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-30T15:01:45.307Z Has data issue: false hasContentIssue false
  • English
  • Français

ADP and arachidonic acid induced platelet aggregation in schizophrenia and atypical psychoses

Published online by Cambridge University Press:  09 July 2009

L. J. Whalley ,
H. W. Reading  and
R. Rosie
L. J. Whalley*
Affiliation:
MRC Brain Metabolism Unit, University Department of Pharmacology, Edinburgh
H. W. Reading
Affiliation:
MRC Brain Metabolism Unit, University Department of Pharmacology, Edinburgh
R. Rosie
Affiliation:
MRC Brain Metabolism Unit, University Department of Pharmacology, Edinburgh
*
1 Address for correspondence: Dr L. J. Whalley MRC Brain Metabolism Unit, University Department of Pharmacology, I George Square, Edinburgh EH8 9JZ.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Platelet aggregatory responses to adenosine diphosphate (ADP) and arachidonic acid were examined in 6 drug-free schizophrenics, 5 other drug-free psychotics, 8 ‘acute-on-chronic’ schizophrenics (on long-term neuroleptic therapy) and 38 healthy controls. Platelet aggregation and disaggregation following ADP was significantly lower in ‘acute-on-chronic’ schizophrenics (on drugs) compared with healthy controls, and disaggregation following 1 µM ADP was significantly less in drug-free schizophrenics. The difference between maximum aggregation induced by ADP and that induced by arachidonic acid was significantly greater in schizophrenics (both on drugs and drug-free) than in controls. These findings are related to possible abnormalities of central nervous system function in schizophrenia.

Type
Brief Communication
Information
Psychological Medicine , Volume 14 , Issue 1 , February 1984 , pp. 207 - 211
Copyright
Copyright © Cambridge University Press 1984

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Abdulla, Y. H. & Hamadah, K. (1975). Effect of ADP on PGE1, formation in blood platelets in depression, mania and schizophrenia. British Journal of Psychiatry 127, 591–595.CrossRefGoogle ScholarPubMed
Arkel, Y. S., Haft, J. E., Kreutner, W., Sherwood, J. & Williams, R. (1977). Alteration in second phase platelet aggregation associated with an emotionally stressful activity. Thrombosis and Haemostasis 38, 552–561.Google ScholarPubMed
Born, G. V. R. (1962). Quantitative investigations into the aggregation of blood platelets. Journal of Physiology (London) 162, 67.Google Scholar
Boullin, D. J. (1981). Platelet shape change in patients with psychiatric disorders and treated with phenothiazines, thiozan-thines, butyrophenones, benzodiazepines, tricyclic antidepressants and β-adrenergic blocking agents. Journal of Neural Transmission 51, 245–256.CrossRefGoogle ScholarPubMed
Boulin, D. J., Bhagavan, H. N., Coleman, M., O'Brien, R. A. & Youdim, M. B. H. (1975). Platelet monoamine oxidase in children with infantile autism. Medical Biology 53, 210–213.Google Scholar
Feldberg, W. (1976). Possible association of schizophrenia with a disturbance in prostaglandin metabolism. Psychological Medicine 6, 359–369.CrossRefGoogle ScholarPubMed
Frojmovic, M. M. & Milton, J. G. (1982). Human platelet size, shape and related functions in health and disease. Physiological Reviews 62, 185–259.CrossRefGoogle ScholarPubMed
Grahame-Smith, D. G., Aronson, J. K., Boullin, D. J. & Orr, M. W. (1976). Cellular biochemical pharmacology in monitoring drug therapy. Arzneimiltel-Forschung (Drug Research) 26, 1256–1257.Google ScholarPubMed
Gross, H. A., Dunner, D. L., Lafleur, D., Meltzer, H. L., Muhlbauer, H. L. & Fieve, R. R. (1977). Prostaglandins: a review of neurophysiology and psychiatric implications. Archives of General Psychiatry 34, 1189–1196.CrossRefGoogle ScholarPubMed
Horrobin, D. F. (1977). Schizophrenia as a prostaglandin deficiency disease. Lancet i, 936–937.CrossRefGoogle Scholar
Horrobin, D. F., Ally, A. I., Karmali, R. A., Karmazyn, M., Manku, M. S. & Morgan, R. O. (1978). Prostaglandins and schizophrenia: further discussion of the evidence. Psychological Medicine 8, 43–48.CrossRefGoogle ScholarPubMed
Passenon, M. K. (1968). Platelet 5-hydroxytryptamine as a model in pharmacology. Annales Medicanae Experimental et Biologiae Fenniae 46, 416–422.Google Scholar
Pletscher, A. (1978). Platelets as models for monoaminergic neurons. In Essays in Neurochemistry and Neuropharmacology, Vol. 13 (ed. Youdim, M. B. H., Lovenberg, W., Sharman, D. F. and Lagnado, J. R.), pp. 48–101. John Wiley and Sons: New York.Google Scholar
Rotrosen, J., Miller, A., Mandio, D., Traficante, L. & Gershon, S. (1978). Reduced PGE1-stimulated 3H-cAMP accumulation in platelets from schizophrenics. Life Sciences 23, 1989–1996.CrossRefGoogle ScholarPubMed
Spitzer, R. L., Endicott, J. & Robins, E. (1978). Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 36, 773–782.CrossRefGoogle Scholar
Stahl, S. M. (1977). The human platelet: a diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Archives of General Psychiatry 34, 509–516.CrossRefGoogle Scholar
Wing, J. K., Cooper, J. E. &Sartorius, N. (1974). The Measurement and Classification of Psychiatric Symptoms. Cambridge University Press: Cambridge.Google Scholar